The HER2/neu (erbB2) polymorphism, body mass index, and the risk of endometrial cancer

被引：0
|
作者：
Lee, J.
Tong, S.
Lee, K.
Kim, J.
Kwon, Y.
Kim, J.
Kim, Y.
Yei, J.
Do, Y.
Kwon, S.
机构：
[1] Kyung Hee Univ, EW Neo Med Ctr, Seoul, South Korea
[2] Gachon Univ, Gil Med Ctr, Inchon, South Korea
[3] Seoul Natl Univ, Coll Med, Seoul, South Korea
[4] Hallym Univ, Coll Med, Seoul, South Korea
[5] Yonsei Univ, Coll Med, Seoul, South Korea
[6] Catholic Univ, Daegu Sch Med, Taegu, South Korea
[7] Keimyung Univ, Sch Med, Taegu, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.22199
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
22199
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancer
    Moutafi, Myrto
    Robbins, Charles J.
    Yaghoobi, Vesal
    Fernandez, Aileen, I
    Martinez-Morilla, Sandra
    Xirou, Vasiliki
    Bai, Yalai
    Song, Yan
    Gaule, Patricia
    Krueger, Joseph
    Bloom, Kenneth
    Hill, Salisha
    Liebler, Daniel C.
    Fulton, Regan
    Rimm, David L.
    LABORATORY INVESTIGATION, 2022, 102 (10) : 1101 - 1108
  • [42] Biosimilar Therapy for ERBB2 (HER2)-Positive Breast Cancer Close Enough?
    Burstein, Harold J.
    Schrag, Deborah
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 317 (01): : 30 - 32
  • [43] Pan-cancer analysis of the influence of ERBB2 alteration on HER2 expression
    Lee, Taebum
    Shin, Sangwon
    Song, Heon
    Park, Seonwook
    Pereira, Sergio
    Yoo, Donggeun
    Ro, Juneyoung
    Moon, Jimin
    Cho, Soo Ick
    Ahn, Changho
    Ock, Chan-Young
    Ali, Siraj M.
    CANCER RESEARCH, 2023, 84 (06)
  • [44] Synthesis and biological evaluation of selective ErbB2 (Her2) inhibitors for the treatment of cancer
    Kauffman, Goss S.
    Lippa, Blaise
    Arcari, Joel
    Kwan, Tricia A.
    Bhattacharya, Samit K.
    Pustilnik, Leslie R.
    Su, Chunyan
    Moyer, James D.
    Ma, Ling
    Campbell, Mary
    Steyn, Stefan
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2006, 231
  • [45] LMO4 is an essential mediator of ErbB2/HER2/Neu-induced breast cancer cell cycle progression
    Montanez-Wiscovich, M. E.
    Seachrist, D. D.
    Landis, M. D.
    Visvader, J.
    Andersen, B.
    Keri, R. A.
    ONCOGENE, 2009, 28 (41) : 3608 - 3618
  • [46] PGDS, a novel technique combining chromogenic in situ hybridization and immunohistochemistry for the assessment of ErbB2 (HER2/neu) status in breast cancer
    Ni, Ruoyu
    Mulligan, Anna Marie
    Have, Cherry
    O'Malley, Frances P.
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2007, 15 (03): : 316 - 324
  • [47] LMO4 is an essential mediator of ErbB2/HER2/Neu-induced breast cancer cell cycle progression
    M E Montañez-Wiscovich
    D D Seachrist
    M D Landis
    J Visvader
    B Andersen
    R A Keri
    Oncogene, 2009, 28 : 3608 - 3618
  • [48] Inhibitors of HER2/neu (erbB-2) signal transduction
    Arteaga, CL
    Chinratanalab, W
    Carter, MB
    SEMINARS IN ONCOLOGY, 2001, 28 (06) : 30 - 35
  • [49] Overexpression of c-Src enhances HER2/Neu/ErbB2 and HER3/ErbB3 heterocomplex formation and its function
    Miyake, Tsuyoshi
    Ishizawar, Rumey C.
    Parsons, Sarah J.
    CANCER RESEARCH, 2006, 66 (08)
  • [50] Influences of apolipoprotein E polymorphism on the risk for breast cancer and HER2/neu status in Taiwan
    Nai-Wen Chang
    Dar-Ren Chen
    Chen-Ten Wu
    Bradley E. Aouizerat
    Fei-Na Chen
    Shin-Jer Hung
    Shiuan-Huei Wang
    Ming-Feng Wei
    Cheng-Shyong Chang
    Breast Cancer Research and Treatment, 2005, 90 : 257 - 261
12345